Format

Send to

Choose Destination
Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):195-203. eCollection 2017.

Dosimetry and first human experience with 89Zr-panitumumab.

Author information

1
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.
2
Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer ResearchFrederick, Maryland 21702, USA.
3
Dana-Farber Cancer InstituteBoston, MA, USA.
4
Stanford University School of MedicinePalo Alto, CA, USA.
5
Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug AdministrationSilver Spring, MD, USA.
6
Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.

Abstract

89Zr-panitumumab is a novel immuno-PET radiotracer. A fully humanized IgG2 antibody, panitumumab binds with high affinity to the extracellular ligand binding domain of EGFR. Immuno-PET with radiolabeled panitumumab is a non-invasive method that could characterize EGFR expression in tumors and metastatic lesions. It might also assist in selecting patients likely to benefit from targeted therapy as well as monitor response and drug biodistribution for dosing guidance. Our objective was to calculate the maximum dosing for effective imaging with minimal radiation exposure in a small subset. Three patients with metastatic colon cancer were injected with approximately 1 mCi (37 MBq) of 89Zr-panitumumab IV. Whole body static images were then obtained at 2-6 hours, 1-3 days and 5-7 days post injection. Whole organ contours were applied to the liver, kidneys, spleen, stomach, lungs, bone, gut, heart, bladder and psoas muscle. From these contours, time activity curves were derived and used to calculate mean resident times which were used as input into OLINDA 1.1 software for dosimetry estimates. The whole body effective dose was estimated between 0.264 mSv/MBq (0.97 rem/mCi) and 0.330 mSv/MBq (1.22 rem/mCi). The organ which had the highest dose was the liver which OLINDA estimated between 1.9 mGy/MBq (7.2 rad/mCi) and 2.5 mGy/MBq (9 rad/mCi). The effective dose is within range of extrapolated estimates from mice studies. 89Zr-panitumumab appears safe and dosimetry estimates are reasonable for clinical imaging.

KEYWORDS:

89Zr-panitumumab; PET; human dosimetry

PMID:
28913158
PMCID:
PMC5596322

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center